ArticleInternational urology and nephrology2026
Exploring the global, regional, and Chinese disease burden of acute glomerulonephritis from 1990 to 2021 and future trends up to 2039 based on the 2021 Global Burden of Disease Database.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute glomerulonephritis (AGN) is a non-infectious inflammation of the glomeruli. Severe AGN can lead to acute renal failure, imposing substantial economic burdens on society. GBD database provided comprehensive data for analyzing global disease trends. Therefore, a thorough assessment of AGN-related burden is essential to inform mitigation strategies.
methodsIn this study, the incidence, mortality, disability-adjusted life years (DALYs), their rates, and corresponding age-standardised rates (ASR) from 1990 to 2021 were systematically described. Trends in the disease burden of AGN across different age groups and genders were further analyzed at the global, regional, and Chinese levels. Additionally, an age-period-cohort model (APCM) was constructed to predict potential future trends.
resultsIn 2021, the incidence, mortality, DALYs, and their corresponding rates of AGN diseases declined significantly globally compared to 1990, yet China maintained relatively high levels of these indicators. Age-stratified analysis showed that individuals aged 0-14 had substantially higher AGN disease burden rates than other age groups. Projections for 2022-2039 indicate rising AGN incidence and age-standardized incidence rate (ASIR), but decreasing mortality/age-standardized mortality rate (ASMR) and DALYs/age-standardized DALYs rate (ASDR). This study highlights the need for increased attention to AGN disease burden in children aged 0-14, China, and regions with medium SDI.
conclusionThis study systematically described the trends of AGN disease at the global, regional, and Chinese levels from 1990 to 2021 and predicted possible future trends. The findings provided valuable tools for assessing the disease burden of AGN.
Indexed as
Identifiers
42223810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.